New York, NY, June 27, 2019 — Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (“TBIs”), including concussions and penetrating injuries, announced today the appointment of John N. Bonfiglio, PhD, MBA as its Chief Operating Officer. Qrons Inc. (OTC: QRON)
Dr. Bonfiglio’s primary responsibility will be to oversee all investigational new drug (“IND”) activities in the United States in coordination with Qrons’ Israeli-based scientific team. [Read more…]